Saniona selects SAN903 as preclinical candidate for treatment of autoimmune disorders
Read more about the program here
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION).
Saniona share (OMX: SANION) is listed on Nasdaq Stockholm Small Cap
We have a broad portfolio of potential drug candidates in preclinical or clinical stages.
SAN711 for treatment of chronic itching and neuropathic pain...See more
SAN903 for treatment of autoimmune disorders...See more
NS2359 – a triple monoamine re-uptake inhibitor for treatment of cocaine abuse...See more